![Julie Feder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Feder
Keine laufenden Positionen mehr
Profil
Julie B. Feder is currently Chief Financial Officer at Obsidian Therapeutics, Inc. Formerly, Ms. Feder was Chief Financial Officer at Aura Biosciences, Inc. from 2018 to 2024, Chief Financial Officer at Verastem, Inc. from 2017 to 2018, Chief Financial Officer at Clinton Health Access Initiative from 2011 to 2017, Vice President-Internal Audit at Genzyme Corp.
from 2008 to 2011, and Senior Manager-Audit, Consulting & Enterprise Risk at Deloitte & Touche LLP from 1991 to 2008.
Ms. Feder completed undergraduate studies at Sy Syms School of Business.
Aktive Positionen von Julie Feder
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Julie Feder
| Unternehmen | Position | Ende |
|---|---|---|
| AURA BIOSCIENCES, INC. | Finanzdirektor/CFO | 25.10.2024 |
| VERASTEM, INC. | Finanzdirektor/CFO | 01.06.2018 |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Finanzdirektor/CFO | 01.07.2017 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Corporate Officer/Principal | 01.01.2008 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Comptroller/Controller/Auditor | - |
Ausbildung von Julie Feder
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
96
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Commercial Services |
Sy Syms School of Business
 Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
